Equities Analysts Offer Predictions for Humacyte Q3 Earnings

Humacyte, Inc. (NASDAQ:HUMA) – Analysts at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for Humacyte in a research note issued on Tuesday, November 5th. HC Wainwright analyst V. Bernardino forecasts that the company will post earnings of ($0.26) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Humacyte’s Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.28) EPS, FY2025 earnings at ($0.76) EPS, FY2026 earnings at ($0.17) EPS and FY2027 earnings at $0.24 EPS.

A number of other equities research analysts have also commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. BTIG Research reaffirmed a “buy” rating and set a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. TD Cowen reaffirmed a “buy” rating and set a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. Finally, EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $11.00.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $5.43 on Thursday. Humacyte has a 1-year low of $2.08 and a 1-year high of $9.97. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61. The business’s 50 day moving average is $5.49 and its 200-day moving average is $6.12. The firm has a market cap of $648.07 million, a P/E ratio of -4.31 and a beta of 1.47.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04).

Insider Transactions at Humacyte

In other Humacyte news, Director Kathleen Sebelius sold 5,182 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the transaction, the director now owns 40,276 shares in the company, valued at approximately $217,490.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Kathleen Sebelius sold 5,182 shares of Humacyte stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the transaction, the director now owns 40,276 shares in the company, valued at approximately $217,490.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Brady W. Dougan sold 352,112 shares of the stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $6.35, for a total value of $2,235,911.20. Following the sale, the director now owns 3,677,262 shares of the company’s stock, valued at $23,350,613.70. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,084,153 shares of company stock worth $6,869,996. Corporate insiders own 11.20% of the company’s stock.

Institutional Investors Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HUMA. Private Advisor Group LLC lifted its stake in shares of Humacyte by 232.7% during the 1st quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock worth $988,000 after purchasing an additional 222,144 shares during the last quarter. Vanguard Group Inc. raised its holdings in Humacyte by 28.7% in the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after buying an additional 896,415 shares during the period. Anson Funds Management LP purchased a new position in Humacyte during the 1st quarter valued at about $156,000. Virtu Financial LLC purchased a new position in Humacyte in the first quarter valued at $197,000. Finally, ARS Investment Partners LLC acquired a new stake in shares of Humacyte in the 2nd quarter valued at $559,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.